Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Health
  • Technology
  • Financial
  • Entertainment
ncarol.com

Eppin Pharma Receives $300,000 Grant for Male Contraception
ncarol.com/10037375

Trending...
  • USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
MCI's total commitment to male contraception now exceeds $3M USD since 2017

DURHAM, N.C. - ncarol.com -- Male Contraceptive Initiative (MCI), a private non-profit foundation, announced four grants, including a grant to Eppin Pharma Inc to support research and development of a male contraceptive, raising MCI's total commitment to male contraception to over $3M USD since 2017.

Eppin Pharma will receive $300,000 to aid in their work developing a novel form of male contraception. Eppin Pharma's product, EP055, is a hormone-free method of contraception that is quickly moving to first-in-human studies. EP055 inhibits sperm motility that is crucial for fertility. The drug is intended to be administered as a pill to men on a daily or on-demand basis, providing protection from pregnancy.

With over $3 million invested in male contraceptive product development, MCI seeks to push male contraceptive research projects towards commercialization. There are a variety of male contraceptive research projects in the drug development pipeline; from early stage screening of drugs to studies that pave the way for early clinical trials, and consistent with their mission, MCI focuses their funding on promising projects within this pipeline like Eppin Pharma's EP055. MCI's mission is to facilitate research and development of male contraceptives for people around the world, and to build awareness among researchers, donors and the general public about the demand for and status of novel male contraceptive methods.

More on ncarol.com
  • OneVizion Appoints Energy Infrastructure Executive Walt Farrell to Board of Directors
  • Tampa Bay Reporter Launches with a Mission to Deliver Local News with National Reach
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME
  • Migguel Anggelo Celebrates the Immigrant Experience, Latino Identity, and the Power of Iconic Latin Rhythms During Hispanic Heritage Month
  • Indianapolis Criminal Defense Firm Rigney Law LLC Relaunches Criminal Law Podcast "Tales from the Brown Desk"

Through its funding efforts, MCI has championed this mission in manifold ways: investing in promising product development through this and other rounds of funding, supporting students and young professionals through fellowships and travel grants, and consistently advocating with the public and media for an increased method mix that includes male contraception.

"More and more men are expressing the desire to participate in contraception with their partners. We are confident that the time is right to emphatically get behind the talent and energy in the field in order to achieve a real vision for a shared contraceptive future," said MCI Executive Director Heather Vahdat.

Dr. Michael O'Rand, CEO and Co-Founder of Eppin added – "We are grateful for the support that MCI has given us and hopeful that this investment in our technology will advance the field of male non-hormonal contraception."

https://www.malecontraceptive.org/

Contact
Kevin Shane
***@malecontraceptive.org


Source: Male Contraceptive Initiative
Filed Under: Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • 2026 Triangle Parade of Homes Features Over 300 Homes
  • "Next Friday" Star Mike Epps Hits Cherokee as KayeDinero Drops "Cherokee"
  • P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
  • Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
  • Travel Season Turns to the Smokies as KayeDinero Turns Cherokee Into a Song
  • DBF Viewer 2000 v9.32 Adds New Control for Data Export
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Cabinet Revolution Expands Affordable Cabinet Options for High Country Homes
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Shuttle Buddy Announces Amazon Partnership to Launch Workforce Express in North Carolina
  • Inlow Upholstery Helps Cleveland County Homeowners Refresh Furniture with Custom Upholstery
  • Birthstones Are Having a 2026 Moment. KayeDinero's "Aquamarine" Began With Her Grandmother
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
_catLbl0 _catLbl1

Popular on ncarol.com

  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 176
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 159
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 149
  • Patented Foodservice Products Company with Strong Gross Margins and Substantial Two-Year Revenue Growth Hits Market for $1.6 Million - 133
  • Vegan Kingz Unveils Upgraded Digital Platform to Streamline Commercial Foodservice & Wholesale Ordering - 123
  • MommyAndMe.club Expands Parent-Child Class Directory to All 50 States and Washington, D.C - 109
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB) - 108
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 108
  • Badanamu and Friends Live Brings Hit Animated Series to Stages Across the United States - 102
  • ChargeOn Announces Conversational Payment Management Solution - 101

Similar on ncarol.com

  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
  • USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season
  • Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute